Laurion Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Laurion Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-52,828	Closed	-$1.07M	–	553
2023 Q4	$1.07M	Buy	+52,828	New	+$695K	0.01%	335
2023 Q2	–	Sell	-21,401	Closed	-$368K	–	631
2023 Q1	$368K	Hold	21,401	–	–	﹤0.01%	358
2022 Q4	$475K	Sell	21,401 -223,722	-91%	-$3.46M	﹤0.01%	357
2022 Q3	$1.97M	Hold	245,123	–	–	0.01%	327
2022 Q2	$1.71M	Hold	245,123	–	–	0.03%	239
2022 Q1	$3.71M	Hold	245,123	–	–	0.05%	174
2021 Q4	$5.38M	Sell	245,123 -30,000	-11%	-$735K	0.05%	188
2021 Q3	$7.42M	Hold	275,123	–	–	0.03%	300
2021 Q2	$6.63M	Sell	275,123 -1,171	-0.4%	-$35.8K	0.04%	250
2021 Q1	$12M	Buy	276,294 +218,294	+376%	+$9.67M	0.06%	235
2020 Q4	$2.4M	Buy	+58,000	New	+$2.39M	0.02%	330

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's FDMT Position: Q1 2024 in Review

Laurion Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2024, closing a stake of 52,828 shares — an estimated $1.07M sold.

Laurion Capital Management first reported a position in FDMT in Q4 2020 and held it in 11 quarters. The position peaked at $12M in Q1 2021. 147 funds tracked by Wall St. Rank hold FDMT as of Q1 2024.

Laurion Capital Management reported no remaining 4D Molecular Therapeutics position as of Q1 2024 after selling out during the quarter.
Laurion Capital Management sold 52,828 4D Molecular Therapeutics shares in Q1 2024, an estimated $1.07M.
Laurion Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 11 quarters.
Laurion Capital Management's 4D Molecular Therapeutics position peaked at $12M in Q1 2021.
147 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.